Search

Your search keyword '"Vencovsky, Jiri"' showing total 413 results

Search Constraints

Start Over You searched for: Author "Vencovsky, Jiri" Remove constraint Author: "Vencovsky, Jiri"
413 results on '"Vencovsky, Jiri"'

Search Results

2. Discovery of new myositis genetic associations through leveraging other immune-mediated diseases

3. Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network

5. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

7. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

8. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies

9. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

10. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

11. Collaborative research in myositis-related disorders: MIHRA, a global shared community model

13. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

14. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

15. Deciphering miRNA Signatures in Axial Spondyloarthritis: The Link between miRNA-1-3p and Pro-Inflammatory Cytokines

16. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

19. Cardiovascular risk in myositis patients compared with the general population.

21. Cardiovascular risk in myositis patients compared with the general population

22. Novel SomaticUBA1Variant in a Patient With VEXAS Syndrome

23. Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.

24. Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.

25. Genome-wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies

27. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies

28. 130 Low Gene Copy Numbers (GCN) of complement C4 and C4A deficiency are highly significant genetic risk factors for idiopathic inflammatory myopathies and its major subgroups

29. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

30. Distinct HLA Associations with Autoantibody-Defined Subgroups in Idiopathic Inflammatory Myopathies

32. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study

33. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

34. The EuroMyositis registry: an international collaborative tool to facilitate myositis research

37. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

38. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects

39. Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome.

40. Identification of Novel Associations and Localization of Signals in Idiopathic Inflammatory Myopathies Using Genome‐Wide Imputation.

41. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies

42. Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study

44. 08.48 Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity

48. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.

50. P222 Clinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry

Catalog

Books, media, physical & digital resources